Relationship Between the Product of Pre‐Treatment Neutrophil and Monocyte Counts and Clinical Outcomes in Rectal Cancer With Suspected Lateral Lymph Node Metastasis
Open Access
- 8 March 2026
- journal article
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (4) , 1097-1106
Abstract
Aim: A novel systemic inflammatory response marker, the neutrophil × monocyte value (NM value), has been identified as a negative predictive factor for responses to chemoradiotherapy in rectal cancer. However, the clinical implications of the NM value remain unknown. Methods: This study reviewed 352 patients with rectal cancer who received preoperative chemoradiotherapy between 2003 and 2023. The cut‐off value for the pre‐treatment NM value was established at the median. A pre‐treatment size of lateral lymph node (LLN) ≥ 8 mm was defined as clinical LLN metastasis. The prognostic significance of the NM value was evaluated. Results: The cut‐off NM value was 1 100 000; 179 patients had an NM value ≥ 1 100 000. Ninety‐nine patients had LLN ≥ 8 mm. Disease‐free survival (DFS) was significantly shorter in patients with an NM value ≥ 1 100 000 than in those with an NM value < 1 100 000. DFS and overall survival (OS) were shorter in patients with LLN ≥ 8 mm than in those with LLN < 8 mm. The LLN size and NM value were identified as independent prognostic factors for DFS (LLN size—hazard ratio (HR): 1.51, p = 0.04, NM value—HR: 1.53, p = 0.04). Patients with LLN ≥ 8 mm and an NM value ≥ 1 100 000 had the poorest prognosis among the populations compared by the combination of LLN size and NM value. Conclusions: The pre‐treatment NM value is an independent prognostic factor associated with DFS. In patients with LLN ≥ 8 mm, a high NM value may be a significant indicator of a poor prognosis.Keywords
This publication has 35 references indexed in Scilit:
- Preoperative chemoradiotherapy with the TEGAFIRI regimen achieves significant local control in locally advanced rectal cancerInternational Journal of Colorectal Disease, 2025
- Systematic review and meta-analysis of long-term oncological outcomes of lateral lymph node dissection for metastatic nodes after neoadjuvant chemoradiotherapy in rectal cancerEuropean Journal of Surgical Oncology, 2022
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancerInternational Journal of Clinical Oncology, 2019
- Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry studyThe Lancet, 2018
- LMR predicts outcome in patients after preoperative chemoradiotherapy for stage II-III rectal cancerJournal of Surgical Research, 2018
- Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8+ Tumor-Infiltrating Lymphocytes Identified Patients With Poor Prognosis in Rectal Cancer: A Matched Comparison AnalysisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
- Factors associated with degree of tumour response to neo-adjuvant radiotherapy in rectal cancer and subsequent corresponding outcomesEuropean Journal of Surgical Oncology, 2017
- Preoperative chemoradiotherapy changes the size criterion for predicting lateral lymph node metastasis in lower rectal cancerInternational Journal of Colorectal Disease, 2017
- Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient dataThe Lancet Oncology, 2010
- Effects of smoking intensity and cessation on inflammatory markers in a large cohort of active smokersAmerican Heart Journal, 2010